FiercePharmaAsia: Takeda, Ascletis, Sanofi, Sun and more

In 2017's first issue of FiercePharmaAsia weekly wrap-up, Takeda spends $35 million on a GI deal, Ascletis is armed with $100 million in the country's HCV drug race, Sanofi's dengue vaccine promotional effort is halted by the Philippines' FDA, fire at Sun Pharma's API plant killed two, and more.

Pfizer, AZ outpace Big Pharma in emerging markets

A few years ago, emerging markets were souped-up engines heating up pharma growth. Now, with economic slowdowns in key markets such as China, they’ve moved into a lower gear—but in the third quarter, drugmakers saw signs of an upward shift, at least in the short term.